MDB Capital/Media/Reports

Highlights

1. $400B+ Market, But Not for Everyone: The U.S. brain-computer interface (BCI) market is real—and enormous. But most of that value will be captured by a small number of companies that move early to secure clinical proof, regulatory alignment, and intellectual property.
2. Innovation ≠ Ownership: Having great tech doesn’t guarantee strategic control. Companies that ignore IP, FDA timelines, or payer strategy will build value—for someone else.
3. Two Markets, Two Playbooks: Enabling BCIs (assistive devices) and preventative BCIs (e.g., seizure prediction) follow different clinical, regulatory, and business paths. Knowing the difference isn’t optional—it defines your IP and go-to-market strategy.
4. IP Is the Battlefield Now: With over 2,160 patent families filed across 664 entities, real strategic ground is already being claimed. The companies consolidating system-level and component-level IP will be impossible to dislodge later.
5. Synchron Is Quietly Beating Neuralink: Forget the headlines—Neuralink may be louder, but Synchron is further along. It reached FDA trials first, secured a global IP footprint, and partnered with Nvidia. Boards betting on visibility over defensibility may be backing the wrong horse.
6. Universities Are Still Ahead of the Market: Institutions like Tianjin University, the University of California, and Stanford own much of the early, foundational IP—often years ahead of commercial deployment. The smartest startups are licensing, not reinventing.
7. A Patent ≠ a Strategy: Most companies file defensively. The leaders file to shape markets. Continuations, indication stacking, and cross-component coverage are how winners build moats.
8. IP Belongs in the Boardroom: Operational IP systems—claim audits, invention pipelines, competitor surveillance—are now mission-critical. If your board isn’t reviewing IP alongside financials, you’re exposed.

READ FULL REPORT HERE

MDB Capital is a wholly-owned subsidiary of MDB Capital Holdings (Nasdaq: MDBH) and a broker-dealer registered with the U.S. Securities and Exchange Commission, a member of FINRA and a member of SIPC. Securities trading, account management, and investment banking services are offered by MDB Capital.

 PatentVest, Inc. is a wholly owned subsidiary of MDB Capital Holdings and an affiliated company of MDB Capital.

 All patent portfolio data and analysis in this report are based on publicly available information as of April 2025, sourced through PatentVest, our proprietary global patent database. While every effort has been made to ensure accuracy and completeness, the findings may not reflect unpublished, pending, or confidential filings. Companies may hold additional IP assets that are not yet publicly disclosed. This report should be considered a snapshot, not a definitive account, of current IP positions.

 Information in this message from employees of MDB Capital or an affiliated company is based upon information that is believed to be reliable. However, neither MDB Capital nor its affiliates warrant its completeness, accuracy or adequacy.

 This message is provided for information purposes only. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product. MDB Capital does not make any representations or warranties concerning the past or future performance of any financial instrument. Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.

 This message and any attachments are intended only for the use of the addressee and may contain confidential, proprietary and/or privileged information. If you are not the intended recipient, any review, use, distribution, dissemination or copying of this email is prohibited. If you have received this email in error, please notify the sender by replying to this message and delete this email immediately.

 To view a listing of all our important disclosures, please visit www.mdb.com/disclosures. For additional information, please visit www.mdb.com or contact us at 945.262.9010.